<p class="MsoNormal">A committee of outside advisers to the United States Food and Drug Administration (USFDA) will on November 6 decide whether to recommend approval for Biogen’s Alzheimer’s drug aducanumab. While USFDA’s final decision is expected by March, European health regulators have also accepted the drug for review.</p>
